WO2016114669A1 - Vaccin combiné pour camélidés - Google Patents

Vaccin combiné pour camélidés Download PDF

Info

Publication number
WO2016114669A1
WO2016114669A1 PCT/NL2016/050040 NL2016050040W WO2016114669A1 WO 2016114669 A1 WO2016114669 A1 WO 2016114669A1 NL 2016050040 W NL2016050040 W NL 2016050040W WO 2016114669 A1 WO2016114669 A1 WO 2016114669A1
Authority
WO
WIPO (PCT)
Prior art keywords
mers
mva
virus
camelids
immunogenic
Prior art date
Application number
PCT/NL2016/050040
Other languages
English (en)
Inventor
Albertus Dominicus Marcellinus Erasmus Osterhaus
Bartholomeus Leonardus Haagmans
Original Assignee
Erasmus University Medical Center Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center Rotterdam filed Critical Erasmus University Medical Center Rotterdam
Publication of WO2016114669A1 publication Critical patent/WO2016114669A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé de prévention d'une infection par la variole du chameau et le coronavirus MERS chez les camélidés, une composition immunogène comprenant le virus MVA en tant que vecteur comprenant un élément immunogène du coronavirus MERS étant administrée aux camélidés. L'invention concerne également l'utilisation de cette composition immunogène à cet effet. De préférence ledit élément immunogène est la protéine de spicule ou un fragment immunogène ou un variant de celle-ci.
PCT/NL2016/050040 2015-01-16 2016-01-18 Vaccin combiné pour camélidés WO2016114669A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014148 2015-01-16
NL2014148A NL2014148B1 (en) 2015-01-16 2015-01-16 Combination vaccine for camelids.

Publications (1)

Publication Number Publication Date
WO2016114669A1 true WO2016114669A1 (fr) 2016-07-21

Family

ID=55538570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2016/050040 WO2016114669A1 (fr) 2015-01-16 2016-01-18 Vaccin combiné pour camélidés

Country Status (2)

Country Link
NL (1) NL2014148B1 (fr)
WO (1) WO2016114669A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380712A (en) 1987-10-30 1995-01-10 Delta Biotechnology Limited Truncated human serum albumin polypeptides as plasma expanding agents
WO2001068820A1 (fr) 2000-03-14 2001-09-20 Anton Mayr Souche d'un virus modifie de vaccine ankara (mva)
WO2014045254A2 (fr) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Lignée c de coronavirus bêta humains et identification de la peptidase dipeptidylique n-terminale en tant que récepteur viral
WO2014134439A1 (fr) * 2013-03-01 2014-09-04 New York Blood Center, Inc. Composition immunogène pour infection de coronavirus de syndrome respiratoire du moyen orient (mers-cov)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380712A (en) 1987-10-30 1995-01-10 Delta Biotechnology Limited Truncated human serum albumin polypeptides as plasma expanding agents
WO2001068820A1 (fr) 2000-03-14 2001-09-20 Anton Mayr Souche d'un virus modifie de vaccine ankara (mva)
WO2014045254A2 (fr) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Lignée c de coronavirus bêta humains et identification de la peptidase dipeptidylique n-terminale en tant que récepteur viral
WO2014134439A1 (fr) * 2013-03-01 2014-09-04 New York Blood Center, Inc. Composition immunogène pour infection de coronavirus de syndrome respiratoire du moyen orient (mers-cov)

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ABDELLATIF, M.M. ET AL., REV. SCI. TECH. OFF. INT. EPIZ., vol. 33, no. 3, 2014, pages 1 - 19
ALTENBURG, A.F. ET AL., VIRUSES, vol. 6, no. 7, 2014, pages 2735 - 2761
ARWEN ALTENBURG ET AL: "Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases", VIRUSES, vol. 6, no. 7, 17 July 2014 (2014-07-17), pages 2735 - 2761, XP055200206, DOI: 10.3390/v6072735 *
F. SONG ET AL: "Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies", JOURNAL OF VIROLOGY, vol. 87, no. 21, 1 November 2013 (2013-11-01), pages 11950 - 11954, XP055157123, ISSN: 0022-538X, DOI: 10.1128/JVI.01672-13 *
GRAESSMANN ET AL., METH. ENZYMOL., vol. 101, 1983, pages 482 - 492
GRAHAM ET AL., VIROL., vol. 52, 1973, pages 456 - 467
HEMIDA, M.G. ET AL., EURO SURVEILLANCE, vol. 18, no. 50, 2013
MAHY, B.W.J.: "The Dictionary of Virology", 2008, ELSEVIER/ACADEMIC PRESS, pages: 74
MANUEL, E. ET AL., VIROLOGY, vol. 403, no. 2, 2010, pages 155 - 162
MAYER, A; CZERNY C.-P.: "Virus Infections of Ruminants", vol. 3, 1990, ELSEVIER SCIENCE PUBL., article "Virus infections of Vertebrates", pages: 19 - 22
MEYER ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038
NEUMANN ET AL., EMBO J., vol. 1, 1982, pages 841 - 845
SCHAFFNER, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 2163 - 2167
SONG ET AL., J. VIROL., vol. 87, no. 21, 2013, pages 11950 - 11954
SONG, F. ET AL., J. VIROL., vol. 87, no. 21, 2013, pages 11950 - 11954
STRAUBINGER ET AL., METH. ENZYMOL., vol. 101, 1983, pages 512 - 527
THELONEVIROLOGIST: "Towards a MERS-CoV vaccine: the importance of S", 22 May 2014 (2014-05-22), XP002756544, Retrieved from the Internet <URL:http://virologytidbits.blogspot.de/2014/05/towards-mers-cov-vaccine-importance-of-s.html> *
WIGLER ET AL., CELL, vol. 16, 1979, pages 777 - 785
WYATT, I.S. ET AL., J. VIROL., vol. 83, no. 14, 2009, pages 7176 - 7184
YOUSIF, A.A.; ALI-ALI, A.M., BIOLOGICALS, vol. 40, pages 495 - 498

Also Published As

Publication number Publication date
NL2014148B1 (en) 2017-01-05
NL2014148A (en) 2016-09-26

Similar Documents

Publication Publication Date Title
JP6130876B2 (ja) 複製欠損性組換えウイルスワクチン中の抗原に対する細胞傷害性ｔ細胞応答に有利である反復ワクチン接種と組み合わされた最適化初期−後期プロモーター
JP4421188B2 (ja) 変性ワクシニアアンカラウイルス変異体
JP6419695B2 (ja) Ｕｌ１２８複合体の送達及びｃｍｖ感染の予防のためのｍｖａワクチン
US9173933B2 (en) Recombinant modified vaccinia virus Ankara influenza vaccine
US20210393766A1 (en) Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine
EA011557B1 (ru) Конструкции нуклеиновых кислот
CN113444156B (zh) 新型冠状病毒肺炎重组人5型腺病毒疫苗
CA2676809C (fr) Protection immediate contre des agents pathogenes par le virus mva modifie
EA024111B1 (ru) Вакцина против вируса африканской чумы лошадей
WO2023077147A2 (fr) Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
NL2014148B1 (en) Combination vaccine for camelids.
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
WO2008150404A1 (fr) Poxvirus du raton laveur exprimant les gènes des antigènes félins
US20120003263A1 (en) Recombinant raccoon pox virus vaccine against highly pathogenic avian influenza
DK2627774T3 (en) INFLUENZAVACCINE BASED ON RECOMBINANT MODIFIED VACCINIAVIRUS ANKARA (VAT)
EP2042604A1 (fr) Surexpression commandée par promoteur VV d&#39;antigènes recombinants
JP2024512103A (ja) ワクチンプラットフォームとしての高弱毒化複製可能組換えポックスウイルスおよびその利用方法
CN113913393A (zh) 新型冠状病毒肺炎的重组新城疫病毒疫苗
US20110177115A1 (en) Vaccination regimen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16710021

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16710021

Country of ref document: EP

Kind code of ref document: A1